Clinical Trial

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-14
Trial Details
NCT Number NCT06233799
Lead Sponsor National Institute on Drug Abuse (NIDA)
Conditions Methamphetamine-dependence, Methamphetamine Abuse
Enrollment 360 participants
Start Date 2024-07-01
Primary Completion 2026-10-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-13